Cargando…
Angiopoietin-like 3 inhibition and the liver: less is more?
PURPOSE OF REVIEW: The aim of this study was to discuss the potential mechanisms and implications of the opposing liver safety results from recent angiopoietin-like 3 (ANGPTL3) inhibition studies. RECENT FINDINGS: The clinical development of vupanorsen, a N-acetylgalactosamine (GalNAc) antisense tar...
Autores principales: | Oostveen, Reindert F., Hovingh, G. Kees, Stroes, Erik S.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624415/ https://www.ncbi.nlm.nih.gov/pubmed/37820081 http://dx.doi.org/10.1097/MOL.0000000000000898 |
Ejemplares similares
-
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
por: Chapman, M. John, et al.
Publicado: (2015) -
Targeting epigenetics as atherosclerosis treatment: an updated view
por: Neele, Annette E., et al.
Publicado: (2020) -
Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations
por: McIntosh, Craig S., et al.
Publicado: (2021) -
ANGPTL3 as therapeutic target
por: Kersten, Sander
Publicado: (2021) -
New algorithms for treating homozygous familial hypercholesterolemia
por: Tromp, Tycho R., et al.
Publicado: (2022)